Drug
Xanomeline clinical trials
Also written BMS-986519.
Counted the way a researcher would: Xanomeline with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
Keep track of what changes. Save the xanomeline studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
40 studies that test it; most in 2025 (16); 1 more planned to start later
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 16 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 37 · Other 4
Bristol-Myers Squibb (18) · Karuna Therapeutics, Inc., a Bristol Myers Squibb company (14) · Karuna Therapeutics (5) · European Group for Research In Schizophrenia (1) · Vanguard Research Group (1) · Collaborative Neuroscience Research, LLC (1) · New York State Psychiatric Institute (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses xanomeline is read from its arms, and is right about nine times in ten.
Testing it · 41
- A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)RecruitingPhase 3Bristol-Myers SquibbNCT06929273Written as KarXT
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I DisorderRecruitingPhase 3Bristol-Myers SquibbNCT06951698Written as KarXT
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)RecruitingPhase 3Bristol-Myers SquibbNCT06951711Written as KarXT
- A Study to Evaluate the Effect of KarXT on Urological SafetyRecruitingPhase 4Bristol-Myers SquibbNCT07221877Written as Xanomeline/trospium chloride
- A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)RecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT06126224Written as KarXT
- Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT05980949Written as KarXT
- A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)RecruitingPhase 3Bristol-Myers SquibbNCT06937229Written as KarXT
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RecruitingPhase 3Bristol-Myers SquibbNCT07011732Written as Xanomeline/Trospium Chloride Capsule
- A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and AdolescentsRecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT07424404Written as KarXT
- A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult ParticipantsRecruitingPhase 1Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT07204418Written as Xanomeline/ Trospium Chloride
- A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)RecruitingPhase 3Bristol-Myers SquibbNCT06976203Written as KarXT
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseaseRecruitingPhase 3Bristol-Myers SquibbNCT07011745Written as Xanomeline/Trospium Chloride Capsule
- A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseRecruitingPhase 3Bristol-Myers SquibbNCT06976216Written as KarXT
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)RecruitingPhase 3Bristol-Myers SquibbNCT07288567Written as KarXT
- A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum DisorderNot yet recruitingPhase 3Bristol-Myers SquibbNCT07285798Written as KarXT
- Relapse Prevention Trial Evaluating KarXT Treatment in SchizophreniaRecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT07686263Written as Xanomeline/Trospium Chloride
- A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)RecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT06585787Written as KarXT
- A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXTRecruitingPhase 1Bristol-Myers SquibbNCT07061288Written as KarXT
- A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With AutismNot yet recruitingPhase 3Bristol-Myers SquibbNCT07284745Written as KarXT
- A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)RecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT05511363Written as KarXT
See all 41 studies that test xanomeline →
Given in every arm · 4 — xanomeline is usual care beside what is tested
- Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersRecruitingPhase 4Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT07681076Written as KarXT
- A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and DigoxinCompletedPhase 1Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT07118215Written as KarXT
- A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy ParticipantsCompletedPhase 1Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT06729970Written as Xanomeline/Trospium Chloride
- Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus TrospiumCompletedPhase 1Karuna TherapeuticsNCT02831231Written as xanomeline tartrate
Codes
What other systems call xanomeline · ClinicalTrials.gg INT003639
- MeSH (NLM) C075257xanomelineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 9ORI6L73CJXANOMELINEConfirmed FDA, NLM, Wikidata
- Wikidata Q8042940xanomelineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152926XanomelineOne source FDA
- DrugBank DB15357One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C075257 | xanomeline | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 9ORI6L73CJ | XANOMELINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q8042940 | xanomeline | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152926 | Xanomeline | One source FDA |
| DrugBank | DB15357 | — | One source Wikidata |
Also registered as xanomeline tartrate (UNII B80W7AUT8R).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.